MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurata, Y.
Right arrow Articles by Narahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurata, Y.
Right arrow Articles by Narahashi, T.

Vol. 55, Issue 6, 1011-1019, June 1999

Agonist and Potentiation Actions of n-Octanol on gamma -Aminobutyric Acid Type A Receptors

Yasutaka Kurata,1 William Marszalec, Jay Z. Yeh, and Toshio Narahashi

Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, Illinois

The n-octanol effects on the gamma -aminobutyric acid type A (GABAA) receptor were studied in human embryonic kidney 293 cells transfected with alpha 1, beta 2, and gamma 2S subunit cDNAs. GABA-evoked currents had an EC50 of 13.3 ± 1.7 µM and a Hill coefficient (nH) of 1.4 ± 0.1. n-Octanol was also capable of evoking a small current with an EC50 of 1000 µM and an nH of 2. In addition, n-octanol modulated GABA-induced currents in a concentration-dependent manner. Coapplications of n-octanol increased peak currents evoked by 3 µM GABA with an EC50 of 190 µM and an nH of 1.8. The extent of potentiation decreased with increasing GABA concentrations and no potentiation was observed when n-octanol was coapplied with 1000 µM GABA. One-minute preapplication of 1000 µM n-octanol slightly potentiated 3 µM GABA-induced current, whereas it suppressed 300 µM GABA-induced current to 16% of the control, suggesting that 84% of the receptors underwent desensitization. Two models were used to explain n-octanol agonistic and potentiating actions on the alpha 1beta 2gamma 2S GABAA receptor: n-octanol binds to multiple sites to exert multiple actions, or n-octanol acts as a partial agonist to manifest these actions. The partial agonist model is unique because it is a simpler model to explain n-octanol actions on the GABAA receptor.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. Liang, E. Cagetti, R. W. Olsen, and I. Spigelman
Altered Pharmacology of Synaptic and Extrasynaptic GABAA Receptors on CA1 Hippocampal Neurons Is Consistent with Subunit Changes in a Model of Alcohol Withdrawal and Dependence
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1234 - 1245.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Rusch, H. Zhong, and S. A. Forman
Gating Allosterism at a Single Class of Etomidate Sites on {alpha}1{beta}2{gamma}2L GABAA Receptors Accounts for Both Direct Activation and Agonist Modulation
J. Biol. Chem., May 14, 2004; 279(20): 20982 - 20992.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Zuo, J. Z. Yeh, and T. Narahashi
Dual Action of n-Butanol on Neuronal Nicotinic alpha 4beta 2 Acetylcholine Receptors
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1143 - 1152.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
D. E. Raines, R. J. Claycomb, and S. A. Forman
Modulation of GABAA Receptor Function by Nonhalogenated Alkane Anesthetics: The Effects on Agonist Enhancement, Direct Activation, and Inhibition
Anesth. Analg., January 1, 2003; 96(1): 112 - 118.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics